POST-TESTFORCME
17. Choose the correct statement concerning cabazitaxel.
a. It is as effective asdocetaxel asfirst line chemotherapy inCRPC.
b. Shouldbeusedwithprophylacticgrowth factor support as second line therapy inCRPC.
c. Has a 1month improvement in survivalwhen compared tomitoxantrone/prednisone.
d. Is approvedby theFDAasfirst line cytotoxic therapy forCRPC.
18. The use of denosumab (120mg subcutaneouslymonthly) or zoledronic acid (4mg IVmonthly) should be
discussed inoneof thesepatients only.
a. Hormonenaïve symptomaticmetastaticpatient startingdegarelix.
b. Nonmetastatic castration resistant patientwithPSAdoubling timeof 6months.
c. Nonmetastaticpatient receiving leuprolideandpresentingwithanosteoporotic fracture. TscoreonDXA
scan= -4.1.
d. Asymptomaticmetastatic castration resistant patientwith increased activityonTc99mbone scan.
19. Whichof the followingbest describes the clinical benefit and toxicityof radium 223:
a. Appropriate for all patientswith castration resistant metastatic prostate cancer following docetaxel, its
use associatedwithmoderatemyelosuppression.
b. Delays time to symptomatic skeletal events,major side effect ishand-foot syndrome.
c. Appropriate for patients with castration resistant metastatic prostate cancer with visceral metastases,
minimal side effect profile.
d. Appropriate for patients with castration resistant metastatic prostate cancer with symptomatic bone
metastases, noknownvisceralmets,mild tomoderateGI toxicity.
20. Whichof the following statements are true:
a. Primary testosteronesuppressionviamedicalorsurgicalcastration isrequiredforoptimaluseofabiraterone
+prednisone.
b. Sipuleucel-T improves overall survival anddelays time to symptomatic skeletal events.
c. Enzalutamide is afirst generation lyase inhibitor.
d. Abiraterone+prednisone improves survival of patientswith castration resistant non-metastaticprostate
cancer.
A14
©TheCanadian Journal ofUrology™: International Supplement, April 2014
